Enfortumab vedotin-ejfv is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3) conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine-citrulline (vc) linker (SGD-1006). Conjugation takes place on cysteine residues that comprise the interchain disulfide bonds of the antibody to yield a product with a drug-to-antibody ratio (DAR) of approximately n = 3.6. The molecular weight is approximately 152 kDa. This product is for research use only.
Product Details |
Species Reactivity | Human |
---|
Type | Antibody-drug conjugate |
---|
ADC antibody | Enfortumab (AGS-22C3) |
---|
ADC cytotoxin (drug) | MMAE |
---|
Immunogen | Nectin-4 |
---|
DAR (Drug to Antibody Ratio) | ~3.6 |
---|
Purity | 99% |
---|
Molecular Weight | 152kDa |
---|
Protein Concentration | 10mg/ml |
---|
Storage Condition | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
---|
Storage Buffer | 100 mM Pro-Ac, 20 mM Arg, pH 5.0 |